First Quarter 2018 Investor Presentation

Investor Presentation First three months of 2018 Slide 24 Novo Nordisk has leading positions in diabetes, haemophilia and obesity Diabetes Obesity DKK billion Market value DKK Market value Novo Nordisk value market share billion Novo Nordisk value market share DKK billion Haemophilia Market value Global market position Global market position Novo Nordisk value market share Global market position 500 400 #1 50% 10 #1 50% #2 80 50% 70 40% 00 8 40% 40% 60 300 30% 6 30% 50 30% 40 CAGR¹ value: 1.9% 200 CAGR¹ value: 15.9% 20% 4 CAGR² value: 49.1% - 20% 30 20% 20 100 10% 2 - 10% 10% 10 0% 0% 0% Feb 2013 Feb 2018 Dec 2015 Dec 2017 FY 2013 FY 2017 1 CAGR for 5-year period Source: IQVIA MAT Feb, 2018 value figures changing diabetes® Note: Value data is based on Australia, Belgium, Brazil, Canada, Chile, Denmark, Germany, Italy, Mexico, Russia, Spain, UAE, USA 2 CAGR for 2-year period Source: IQVIA MAT Dec, 2017 value figures Note: Annual sales figures for Haemophilia A, B and Bypassing agents segment. Recombinant and plasmal derived products Source: Company reports novo nordisk

View entire presentation